UroGen Pharma is performing  safety and efficacy clinical trials in several urinary tract indications: UTUC and bladder cancer in leading centers in USA, Europe and Israel:

UTUCBack to top

olympus

The OLYMPUS study –  Optimized DeLivery of Mitomycin for Primary UTUC Study
A  Study Evaluating The Feasibility, Safety, Durability and Ablative Effect of MitoGel (Mitomycin C mixed with RTGel) in Patients With Upper Tract Urothelial Cancer.
Commencement of patient recruitment planned for H1 2017.

LOW GRADE BLADDER CANCERBack to top

 optima 

The OPTIMA study – OPTimized Instillation of Mitomycin for BlAdder Cancer Treament. A Prospective, Open Label, Comparative Dose Escalation Study Evaluating the Chemoablative Effect of  Intravesical Instillation of Mitomycin C (MMC) Mixed with RTGel in Patients with Non Muscle Invasive Bladder Cancer (NMIBC).
Study conducted in Europe and Israel. COMPLETED PATIENT RECRUITMENT.


The OPTIMA study II – OPTimized Instillation of Mitomycin for BlAdder Cancer Treament. A Prospective, Open Label Study Evaluating the Chemoablative Effect of  Intravesical Instillation of VesiGel in Patients with Non Muscle Invasive Bladder Cancer (NMIBC).
Commencement of patient recruitment planned for Q3 2017.

CARCINOMA IN SITUBack to top

Pilot, Open-label, phase II study, investigating the response to intravesical TMX‑101 (Vesimune) in patients with CIS bladder cancer. Phase I study under IND.
COMPLETED

UTUC

olympus

The OLYMPUS study –  Optimized DeLivery of Mitomycin for Primary UTUC Study
A  Study Evaluating The Feasibility, Safety, Durability and Ablative Effect of MitoGel (Mitomycin C mixed with RTGel) in Patients With Upper Tract Urothelial Cancer.
Commencement of patient recruitment planned for H1 2017.

LOW GRADE BLADDER CANCER

 optima 

The OPTIMA study – OPTimized Instillation of Mitomycin for BlAdder Cancer Treament. A Prospective, Open Label, Comparative Dose Escalation Study Evaluating the Chemoablative Effect of  Intravesical Instillation of Mitomycin C (MMC) Mixed with RTGel in Patients with Non Muscle Invasive Bladder Cancer (NMIBC).
Study conducted in Europe and Israel. COMPLETED PATIENT RECRUITMENT.


The OPTIMA study II – OPTimized Instillation of Mitomycin for BlAdder Cancer Treament. A Prospective, Open Label Study Evaluating the Chemoablative Effect of  Intravesical Instillation of VesiGel in Patients with Non Muscle Invasive Bladder Cancer (NMIBC).
Commencement of patient recruitment planned for Q3 2017.

CARCINOMA IN SITU

Pilot, Open-label, phase II study, investigating the response to intravesical TMX‑101 (Vesimune) in patients with CIS bladder cancer. Phase I study under IND.
COMPLETED